Docoh
Loading...

16 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
in evaluation period and surgical technique, and due to varying patient characteristics including demographic factors and health status. Even though we may
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
, such as local standards of care, differences in evaluation period and surgical technique, and due to varying patient characteristics including demographic
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
in evaluation period and surgical technique, and due to varying patient characteristics including demographic factors and health status. Even though
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
technique, and due to varying patient characteristics including demographic factors and health status. Even though we may apply for orphan drug
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
demographic factors and health status. Even though we may apply for orphan drug designation for a product candidate, we may not be able to obtain orphan
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
characteristics including demographic factors and health status. Even though we may apply for orphan drug designation for a product candidate, we may not be able
S-1
PCSA Processa Pharmaceuticals Inc
13 Dec 19
IPO registration
5:32pm
in evaluation period and surgical technique, and due to varying patient characteristics including demographic factors and health status. Even though
10-K/A
2018 FY
PCSA Processa Pharmaceuticals Inc
5 Apr 19
Annual report (amended)
9:40pm
patient characteristics including demographic factors and health status. Even though we may apply for orphan drug designation for a product candidate, we
10-K
2018 FY
PCSA Processa Pharmaceuticals Inc
28 Mar 19
Annual report
5:25pm
patient characteristics including demographic factors and health status. Even though we may apply for orphan drug designation for a product candidate, we
424B3
PCSA Processa Pharmaceuticals Inc
9 Nov 18
Prospectus supplement
5:04pm
and surgical technique, and due to varying patient characteristics including demographic factors and health status. Even though we may apply
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Oct 18
IPO registration (amended)
4:19pm
of care, differences in evaluation period and surgical technique, and due to varying patient characteristics including demographic factors and health
S-1/A
PCSA Processa Pharmaceuticals Inc
9 Oct 18
IPO registration (amended)
5:32pm
, and due to varying patient characteristics including demographic factors and health status. Even though we may apply for orphan drug designation
S-1/A
PCSA Processa Pharmaceuticals Inc
13 Sep 18
IPO registration (amended)
8:00pm
including demographic factors and health status. Even though we may apply for orphan drug designation for a product candidate, we may not be able
S-1
PCSA Processa Pharmaceuticals Inc
29 Jul 18
IPO registration
8:00pm
standards of care, differences in evaluation period and surgical technique, and due to varying patient characteristics including demographic factors
10-K/A
2017 FY
PCSA Processa Pharmaceuticals Inc
16 Apr 18
Annual report (amended)
8:00pm
to varying patient characteristics including demographic factors and health status. Even though we may apply for orphan drug designation
10-K
2017 FY
PCSA Processa Pharmaceuticals Inc
15 Apr 18
Annual report
8:00pm
demographic factors and health status. Even though we may apply for orphan drug designation for a product candidate, we may not be able to obtain
  • 1